COVID-19 VACCINATION PERFORMANCE ANALYSIS FOR THE UNITED STATES AND INDIA

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is an ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Amidst the pandemic pharmaceutical companies and health care centers have been trying relentlessly to combat the virus and vaccination is recently available. The COVID-19 vaccination campaign in the United States is an ongoing mass immunization campaign for the COVID-19 pandemic. Mass vaccinations began on December 14, 2020. The vaccines that are currently prevailing under the FDA's emergency use of authorization are Pfizer–BioNTech vaccine, Moderna vaccine, and Johnson & Johnson vaccine. Free vaccination against COVID-19 commenced in India on January 16, 2021, and the government is urging all its citizens to be immunized, in what is expected to be the largest vaccination program in the world. The Indian government has taken urgent measures to expand the country's vaccine manufacturing capacity and has also developed an efficient digital system to address and monitor all the aspects of vaccine administration. India's drug regulator has approved restricted emergency use of Covishield (the name employed in India for the Oxford-AstraZeneca vaccine) and Covaxin, the home-grown vaccine produced by Bharat Biotech. The timely and coordinated execution of these post-efficacy tasks will bring the pandemic to an effective and efficient ending. In this research, it has been studied COVID-19 vaccination trends of the United States and India with the aspects of region, states/union territory, age, and gender.